Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 777 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: attention placebo Clear all
Completed Phase 3 Interventional Results available

Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

NCT00856973
View directory record Official record
Conditions
Insomnia, Attention Deficit Hyperactivity Disorder
Interventions
eszopiclone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
73
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 7, 2026, 6:34 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population

NCT06837246
View directory record Official record
Conditions
Cognition, Concentration, Attention, Focus
Interventions
Cognitive Nutritional Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Pharmavite LLC
Industry
Eligibility
25 Years to 65 Years
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 7, 2026, 6:34 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Cannabidiol in Sanfilippo Syndrome

NCT06333041
View directory record Official record
Conditions
Sanfilippo Syndrome, Mucopolysaccharidosis III
Interventions
Epidiolex, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
4 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 7, 2026, 6:34 AM EDT
Recruiting Phase 3 Interventional

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

NCT06736574
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions
Omecamtiv Mecarbil (OM), Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
88
States / cities
Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Phase 4 Interventional

Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial

NCT00343876
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
aspirin, clopidogrel
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Phase 3 Interventional

Testing the Effectiveness of a Computer-based Program for Depression

NCT01203683
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active computer-based training, Inert computer training
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Postpartum Smoking Relapse Prevention by Breastfeeding Promotion

NCT04670822
View directory record Official record
Conditions
Smoking, Cigarette, Breastfeeding
Interventions
Breastfeeding promotion, Attention placebo control
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Phase 4 Interventional Results available

Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children

NCT00254462
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Placebo, Parent Training
Drug · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
5 Years to 6 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Omaha, Nebraska • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Phase 3 Interventional

CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD

NCT00641329
View directory record Official record
Conditions
ADHD
Interventions
CLONICEL (clonidine HCl sustained release), Placebo
Drug
Lead sponsor
Addrenex Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
23
States / cities
Little Rock, Arkansas • El Centro, California • Irvine, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2010 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Not applicable Interventional Results available

Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)

NCT00702364
View directory record Official record
Conditions
Traumatic Brain INjury
Interventions
atomoxetine, placebo
Drug
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Phase 4 Interventional Results available

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
View directory record Official record
Conditions
Pervasive Development Disorders
Interventions
placebo, extended-release guanfacine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
5 Years to 14 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 7, 2026, 6:34 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

MANP in African Americans With Hypertension

NCT04542681
View directory record Official record
Conditions
Hypertension, Resistant to Conventional Therapy
Interventions
Placebo - 1st Cycle, MANP - 1st Cycle, MANP - 2nd Cycle
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection

NCT03099863
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Cystoscopic Fluid containing Neosporin G. U. Irrigant, Cystoscopy, Cystoscopic Fluid/Placebo
Drug · Procedure
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Not applicable Interventional Results available

Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)

NCT00453921
View directory record Official record
Conditions
Brain Injury
Interventions
Methylphenidate, Memory and Attention Training, Placebo as both treatments
Drug · Behavioral · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Denver, Colorado • Indianapolis, Indiana • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 7, 2026, 6:34 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Modulation of Brain Oscillations Underlying Working Memory

NCT05923606
View directory record Official record
Conditions
Working Memory
Interventions
Active tACS, Placebo tACS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

NCT05683249
View directory record Official record
Conditions
ADHD
Interventions
NRCT-101-SR, Placebo
Drug
Lead sponsor
Neurocentria, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Garden Grove, California • Lakeland, Florida • Maitland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

NCT01081132
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Extended-release Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Dothan, Alabama • Little Rock, Arkansas • Rolling Hills Estates, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Intermittent Hypoxia (IH) on Metabolism and Dysglycemia, in Overweight/Obese Persons SCI

NCT02973438
View directory record Official record
Conditions
Spinal Cord Injuries, Obesity, Insulin Resistance
Interventions
Intermittent Hypoxia (IH), SHAM
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 7, 2026, 6:34 AM EDT
Terminated Not applicable Interventional Results available

Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

NCT01100658
View directory record Official record
Conditions
ALL, Childhood, Leukemia, Lymphoblastic, Leukemia, Lymphoblastic, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Acute, L1, Leukemia, Lymphocytic, Acute, L2, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute, L1, Lymphoblastic Leukemia, Acute, L2, Lymphoblastic Lymphoma, Lymphocytic Leukemia, Acute, Lymphocytic Leukemia, L1, Lymphocytic Leukemia, L2, Brain Tumors, Cancer of the Brain, Cancer of Brain, Malignant Primary Brain Tumors, Brain Neoplasms, Malignant
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
8 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 7, 2026, 6:34 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment

NCT04620109
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
KDR2-2, Placebo
Drug
Lead sponsor
Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

NCT01532414
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Mobile, Alabama • Little Rock, Arkansas • Garden Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Not applicable Interventional Results available

Valproate for Mood Swings and Alcohol Use Following Head Injury

NCT01760785
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Alcoholism
Interventions
divalproex sodium, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project Talk Trial: Engaging Underserved Communities in End-of-life Conversations

NCT04612738
View directory record Official record
Conditions
Advance Care Planning, Advance Directives, Terminal Illness, Chronic Illness, Communication
Interventions
Hello (serious game), The Conversation Project (CP) Starter Kit, Table Topics (general conversation game)
Behavioral · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
79
States / cities
Athens, Alabama • Kingman, Arizona • Show Low, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 7, 2026, 6:34 AM EDT
Completed Not applicable Interventional Results available

Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)

NCT01408901
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Supervised Treadmill Exercise Therapy, Health education sessions (Control), granulocyte macrophage colony stimulating factor (GM-CSF)
Behavioral · Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 7, 2026, 6:34 AM EDT